Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
National Institutes of Diabetes and Digestive and Kidney Diseases
Semaglutide (Ozempic) and tirzepatide (Mounjaro) are FDA-approved only for type 2 diabetes management, not for weight loss
Eligible adult patients (BMI 27, glycated hemoglobin 7-10% [53-86 mmol/mol]) ( n = 938) were randomized (1:1:1) to receive tirzepatide 10 mg, 15 mg, or a matching placebo as a subcutaneous once-weekly injection for 72 weeks
These factors are important to consider in the quest to enhance antiaging influences and expand the healthspan of humans in the future [9, 16]
US$ 24.43
US$ 20.78
US$ 26.69
US$ 21.60
US$ 22.46
US$ 25.90
